Skip to main content
ORIC
NASDAQ Life Sciences

ORIC Q3: $345M Cash to 2H 2028, Phase 3 Started in Prostate Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.52
Mkt Cap
$779.468M
52W Low
$7.23
52W High
$14.68
52W Position info
4.0% above low
Off High info
49% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ORIC is trading near its 52-week low of $7.23 (4.0% above the low).

Summary

ORIC reported Q3 2026 results with $345.4M in cash, enough to fund operations into 2H 2028, and disclosed that its first Phase 3 trial (Himalayas-1) is now underway with Bayer supplying darolutamide.


Key Events · Earnings and Guidance · ORIC

  • Q3 Results and Cash Runway

    Cash, cash equivalents and investments totaled $345.4 million as of September 30, 2026, expected to fund the operating plan into 2H 2028 and beyond the first Phase 3 rinzimetostat readout.

  • Loss Widens on Rinzimetostat Spend

    R&D expenses rose to $43.4 million from $28.8 million a year earlier, and the net loss widened to $48.1 million ($0.44 per share) from $32.6 million ($0.33).

  • First Phase 3 Trial Initiated

    Himalayas-1 will enroll approximately 600 patients across 250+ sites in 25 countries, randomizing rinzimetostat plus darolutamide against physician's choice of an AR inhibitor or docetaxel.

  • Bayer to Supply Darolutamide Free

    A clinical trial collaboration and supply agreement has Bayer providing NUBEQA at no cost for Himalayas-1; ORIC keeps full global development and commercial rights to rinzimetostat.


Analysis · ORIC · Life Sciences

The quarter itself is unremarkable — R&D spend rose to $43.4M from $28.8M and the net loss widened to $48.1M — but the program updates are what matter. ORIC has now started its first Phase 3 (Himalayas-1, ~600 patients) in post-abiraterone mCRPC with Bayer supplying darolutamide at no cost, and it plans a second Phase 3 (Redwood-1) in EGFR atypical NSCLC in 1H 2027. With $345.4M in cash funding operations into 2H 2028 and past the first Phase 3 readout, the company does not need to raise money near its 52-week low to reach that data point.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ORIC was trading at $7.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.5M. The 52-week trading range was $7.23 to $14.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ORIC - Latest Insights

ORIC
Nov 16, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.81 info
Change: +$0.290 (+4%) info
Market Cap: $779.468M info
ORIC
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.81 info
Change: +$0.290 (+4%) info
Market Cap: $779.468M info
ORIC
Oct 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.32
Real-time Price: $7.81 info
Change: -$5.51 (-41%) info
Market Cap: $779.468M info
ORIC
Oct 23, 2026, 3:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $13.85
Real-time Price: $7.81 info
Change: -$6.04 (-44%) info
Market Cap: $779.468M info
ORIC
Aug 03, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.58
Real-time Price: $7.81 info
Change: -$2.77 (-26%) info
Market Cap: $779.468M info